The essential role of Epstein-Barr virus in the pathogenesis of multiple sclerosis

Neuroscientist

Volumn 17, Issue 4, 2011, Pages 351-367

  Pender, Michael P ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

autoimmune; CD8 T cell; Epstein Barr virus; multiple sclerosis; sunlight; treatment; vitamin D

Indexed keywords

AUTOANTIBODY; EPSTEIN BARR VIRUS ANTIGEN 1; VITAMIN D;

ANTIBODY PRODUCTION; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; DISEASE PREDISPOSITION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HUMAN; HYPOTHESIS; INFECTION CONTROL; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SUNLIGHT; VITAMIN INTAKE;

AUTOANTIBODIES; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; MULTIPLE SCLEROSIS; T-LYMPHOCYTE SUBSETS;

EID: 79958728110     PISSN: 10738584     EISSN: 10894098     Source Type: Journal    
DOI: 10.1177/1073858410381531     Document Type: Article

References (111)

1. Acheson ED, Bachrach CA, Wright FM. Some comments on the relationship of the distribution of multiple sclerosis to latitude, solar radiation, and other variables. Acta Psychiatr Scand Suppl. 1960 ; 35: 132-47
2. Amadori A, Zamarchi R, De Silvestro G, Forza G, Cavatton G, Danieli GA. Genetic control of the CD4/CD8 T-cell ratio in humans. Nat Med. 1995 ; 1: 1279-83
3. Antel JP, Peeples DM, Reder AT, Arnason BGW. Analysis of T regulator cell surface markers and functional properties in multiple sclerosis. J Neuroimmunol. 1984 ; 6: 93-103 (Pubitemid 14148132)
4. Armengol MP, Juan M, Lucas-Martín A, Fernández-Figueras MT, Jaraquemada D, Gallart T. Thyroid autoimmune disease: demonstration of thyroid antigen-specific B cells and recombination-activating gene expression in chemokine-containing active intrathyroidal germinal centers. Am J Pathol. 2001 ; 159: 861-73 (Pubitemid 32847177)
5. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis: Part I. The role of infection. Ann Neurol. 2007 ; 61: 288-99 (Pubitemid 46676728)
6. Ascherio A, Munger KL, Lennette ET, Spiegelman D, Hernán MA, Olek MJ. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA. 2001 ; 286: 3083-8 (Pubitemid 34016522)
7. Bach M-A, Phan-Dinh-Tuy F, Tournier E, Chatenoud L, Bach J-F, Martin C. Deficit of suppressor T cells in active multiple sclerosis. Lancet. 1980 ; 316: 1221-3 (Pubitemid 11250857)
8. Banwell B, Krupp L, Kennedy J, Tellier R, Tenembaum S, Ness J. Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol. 2007 ; 6: 773-81 (Pubitemid 47238663)
9. Bech E, Lycke J, Gadeberg P, Hansen HJ, Malmeström C, Andersen O. A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS. Neurology. 2002 ; 58: 31-6 (Pubitemid 34041934)
10. Becklund BR, Severson KS, Vang SV, DeLuca HF. UV radiation suppresses experimental autoimmune encephalomyelitis independent of vitamin D production. Proc Natl Acad Sci U S A. 2010 ; 107: 6418-23
11. Booss J, Esiri MM, Tourtellotte WW, Mason DY. Immunohistological analysis of T lymphocyte subsets in the central nervous system in chronic progressive multiple sclerosis. J Neurol Sci. 1983 ; 62: 219-32 (Pubitemid 14176251)
12. Bray PF, Bloomer LC, Salmon VC, Bagley MH, Larsen PD. Epstein-Barr virus infection and antibody synthesis in patients with multiple sclerosis. Arch Neurol. 1983 ; 40: 406-8 (Pubitemid 13060499)
13. Brennan RM, Burrows JM, Bell MJ, Bromham L, Csurhes PA, Lenarczyk A. Strains of Epstein-Barr virus infecting multiple sclerosis patients. Multiple Sclerosis. 2010 ; 16: 643-51
14. Çakmak FN, Erol M, Ergül P, Yalçner A. T lymphocytes and vitamins. J Pediatr. 1999 ; 135: 531
15. Cepok S, Zhou D, Srivastava R, Nessler S, Stei S, Büssow K. Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest. 2005 ; 115: 1352-60 (Pubitemid 40629055)
16. Confavreux C, Vukusic S. Age at disability milestones in multiple sclerosis. Brain. 2006 ; 129: 595-605 (Pubitemid 43278222)
17. Correale J, Fiol M, Gilmore W. The risk of relapses in multiple sclerosis during systemic infections. Neurology. 2006 ; 67: 652-9 (Pubitemid 44273613)
18. Craig JC, Haire M, Merrett JD. T-cell-mediated suppression of Epstein-Barr virus-induced B lymphocyte activation in multiple sclerosis. Clin Immunol Immunopathol. 1988 ; 48: 253-60
19. Falkenbach A, Sedlmeyer A. Travel to sunny countries is associated with changes in immunological parameters. Photodermatol Photoimmunol Photomed. 1997 ; 13: 139-42 (Pubitemid 28023152)
20. Farrell RA, Antony D, Wall GR, Clark DA, Fisniku L, Swanton J. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology. 2009 ; 73: 32-8
21. Ferreira MAR, Mangino M, Brumme CJ, Zhao ZZ, Medland SE, Wright MJ. Quantitative trait loci for CD4:CD8 lymphocyte ratio are associated with risk of type 1 diabetes and HIV-1 immune control. Am J Hum Genet. 2010 ; 86: 88-92
22. Fraser KB, Millar JHD, Haire M, McCrea S. Increased tendency to spontaneous in-vitro lymphocyte transformation in clinically active multiple sclerosis. Lancet. 1979 ; 314: 715-7 (Pubitemid 10210201)
23. Galea I, Bernardes-Silva M, Forse PA, van Rooijen N, Liblau RS, Perry VH. An antigen-specific pathway for CD8 T cells across the blood-brain barrier. J Exp Med. 2007 ; 204: 2023-30 (Pubitemid 47360864)
24. Goldberg P. Multiple sclerosis: vitamin D and calcium as environmental determinants of prevalence (a viewpoint): Part 1. Sunlight, dietary factors and epidemiology. Int J Environ Stud. 1974 ; 6: 19-27
25. Grant WB. Hypothesis-ultraviolet-B irradiance and vitamin D reduce the risk of viral infections and thus their sequelae, including autoimmune diseases and some cancers. Photochem Photobiol. 2008 ; 84: 356-65 (Pubitemid 351421386)
26. Gulley ML, Tang W. Laboratory assays for Epstein-Barr virus-related disease. J Mol Diagn. 2008 ; 10: 279-92 (Pubitemid 352022708)
27. Haahr S, Höllsberg P. Multiple sclerosis is linked to Epstein-Barr virus infection. Rev Med Virol. 2006 ; 16: 297-310 (Pubitemid 44497311)
28. Hadinoto V, Shapiro M, Greenough TC, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. On the dynamics of acute EBV infection and the pathogenesis of infectious mononucleosis. Blood. 2008 ; 111: 1420-7 (Pubitemid 351213429)
29. Hadinoto V, Shapiro M, Sun CC, Thorley-Lawson DA. The dynamics of EBV shedding implicate a central role for epithelial cells in amplifying viral output. PLoS Pathog. 2009 ; 5: e1000496
30. Hall MA, Ahmadi KR, Norman P, Snieder H, MacGregor AJ, Vaughan RW. Genetic influence on peripheral blood T lymphocyte levels. Genes Immun. 2000 ; 1: 423-7
31. Haque T, Johannessen I, Dombagoda D, Sengupta C, Burns DM, Bird P. A mouse monoclonal antibody against Epstein-Barr virus envelope glycoprotein 350 prevents infection both in vitro and in vivo. J Infect Dis. 2006 ; 194: 584-7 (Pubitemid 44297842)
32. Hauser SL, Bhan AK, Gilles F, Kemp M, Kerr C, Weiner HL. Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions. Ann Neurol. 1986 ; 19: 578-87 (Pubitemid 16085192)
33. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008 ; 358: 676-88 (Pubitemid 351240747)
34. Hersey P, Bradley M, Hasic E, Haran G, Edwards A, McCarthy WH. Immunological effects of solarium exposure. Lancet. 1983a ; 321: 545-8 (Pubitemid 13152246)
35. Hersey P, Haran G, Hasic E, Edwards A. Alteration of T cell subsets and induction of suppressor T cell activity in normal subjects after exposure to sunlight. J Immunol. 1983b ; 31: 171-4 (Pubitemid 13069271)
36. Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol. 2007 ; 25: 587-617 (Pubitemid 46697918)
37. Hochberg D, Souza T, Catalina M, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. Acute infection with Epstein-Barr virus targets and overwhelms the peripheral memory B-cell compartment with resting, latently infected cells. J Virol. 2004 ; 78: 5194-204 (Pubitemid 38581471)
38. Holmøy T. Vitamin D status modulates the immune response to Epstein Barr virus: synergistic effect of risk factors in multiple sclerosis. Med Hypotheses. 2008 ; 70: 66-9 (Pubitemid 350167496)
39. Hoshino Y, Morishima T, Kimura H, Nishikawa K, Tsurumi T, Kuzushima K. Antigen-driven expansion and contraction of CD8+-activated T cells in primary EBV infection. J Immunol. 1999 ; 163: 5735-40
40. Jaquiéry E, Jilek S, Schluep M, Meylan P, Lysandropoulos A, Pantaleo G. Intrathecal immune responses to EBV in early MS. Eur J Immunol. 2010 ; 40: 878-87
41. Jilek S, Schluep M, Meylan P, Vingerhoets F, Guignard L, Monney A. Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis. Brain. 2008 ; 131: 1712-21 (Pubitemid 351957461)
42. Kelly GL, Long HM, Stylianou J, Thomas WA, Leese A, Bell AI. An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in Burkitt lymphomagenesis: the Wp/BHRF1 link. PLoS Pathog. 2009 ; 5: e1000341
43. Kreuzfelder E, Shen G, Bittorf M, Scheiermann N, Thraenhart O, Seidel D. Enumeration of T, B and natural killer peripheral blood cells of patients with multiple sclerosis and controls. Eur Neurol. 1992 ; 32: 190-4
44. Laichalk LL, Thorley-Lawson DA. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J Virol. 2005 ; 79: 1296-307 (Pubitemid 40053911)
45. Lang HL, Jacobsen H, Ikemizu S, Andersson C, Harlos K, Madsen L. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol. 2002 ; 3: 940-3 (Pubitemid 35154007)
46. Lemire JM, Archer DC. 1,25-Dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest. 1991 ; 87: 1103-7
47. Levin LI, Munger KL, O'Reilly EJ, Falk KI, Ascherio A. Primary infection with the Epstein-Barr virus and risk of multiple sclerosis. Ann Neurol. 2010 ; 67: 824-30
48. Levin LI, Munger KL, Rubertone MV, Peck CA, Lennette ET, Spiegelman D. Temporal relationship between elevation of Epstein-Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA. 2005 ; 293: 2496-500 (Pubitemid 40705731)
49. Li N, Thompson S, Schultz DC, Zhu W, Jiang H, Luo C. Discovery of selective inhibitors against EBNA1 via high throughput in silico virtual screening. PLoS One. 2010 ; 5: e10126
50. Lünemann JD, Edwards N, Muraro PA, Hayashi S, Cohen JI, Münz C. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain. 2006 ; 129: 1493-506 (Pubitemid 43999382)
51. Lünemann JD, Huppke P, Roberts S, Brück W, Gärtner J, Münz C. Broadened and elevated humoral immune response to EBNA1 in pediatric multiple sclerosis. Neurology. 2008a ; 71: 1033-5
52. Lünemann JD, Jel I, Roberts S, Lutterotti A, Tackenberg B, Martin R. EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-g and IL-2. J Exp Med. 2008b ; 205: 1763-73
53. Lünemann JD, Tintoré M, Messmer B, Strowig T, Rovira A, Perkal H. Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. Ann Neurol. 2010 ; 67: 159-69
54. Lycke J, Svennerholm B, Hjelmquist E, Frisen L, Badr G, Andersson M. Acyclovir treatment of relapsing-remitting multiple sclerosis: a randomized, placebo-controlled, double-blind study. J Neurol. 1996 ; 243: 214-24
55. Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007 ; 130: 1089-104 (Pubitemid 47355604)
56. Mancao C, Hammerschmidt W. Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival. Blood. 2007 ; 110: 3715-21 (Pubitemid 350159641)
57. McCarthy NJ, Hazlewood SA, Huen DS, Rickinson AB, Williams GT. The Epstein-Barr virus gene BHRF1, a homologue of the cellular oncogene Bcl-2, inhibits apoptosis induced by gamma radiation and chemotherapeutic drugs. Adv Exp Med Biol. 1996 ; 406: 83-97 (Pubitemid 26357344)
58. Mei YP, Zhu XF, Zhou JM, Huang H, Deng R, Zeng YX. siRNA targeting LMP1-induced apoptosis in EBV-positive lymphoma cells is associated with inhibition of telomerase activity and expression. Cancer Lett. 2006 ; 232: 189-98 (Pubitemid 43170968)
59. Michaowska-Wender G, Wender M. Mononuclear subsets in the peripheral blood of multiple sclerosis patients in relation to results of brain gadolinium-enhancing imaging. Folia Neuropathol. 2006 ; 44: 67-71
60. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA. 2006 ; 296: 2832-8 (Pubitemid 44969183)
61. Munger KL, Zhang SM, O'Reilly E, Hernán MA, Olek MJ, Willett WC. Vitamin D intake and incidence of multiple sclerosis. Neurology. 2004 ; 62: 60-5 (Pubitemid 38082871)
62. Nemerow GR, Mold C, Schwend VK, Tollefson V, Cooper NR. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d. J Virol. 1987 ; 61: 1416-20 (Pubitemid 17069728)
63. Nonnecke BJ, Franklin ST, Reinhardt TA, Horst RL. In vitro modulation of proliferation and phenotype of resting and mitogen-stimulated bovine mononuclear leukocytes by 1,25-dihydroxyvitamin D3. Vet Immunol Immunopathol. 1993 ; 38: 75-89
64. Peferoen LAN, Lamers F, Lodder LNR, Gerritsen WH, Huitinga I, Melief J. Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis. Brain. 2010 ; 133: e137
65. Pender MP. Genetically determined failure of activation-induced apoptosis of autoreactive T cells as a cause of multiple sclerosis. Lancet. 1998 ; 351: 978-81 (Pubitemid 28138482)
66. Pender MP. Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends Immunol. 2003 ; 24: 584-8 (Pubitemid 37338526)
67. Pender MP. Preventing and curing multiple sclerosis by controlling Epstein-Barr virus infection. Autoimmun Rev. 2009a ; 8: 563-568
68. Pender MP. Does Epstein-Barr virus infection in the brain drive the development of multiple sclerosis?. Brain. 2009b ; 132: 3196-8
69. Pender MP, Csurhes PA, Lenarczyk A, Pfluger CMM, Burrows SR. Decreased T cell reactivity to Epstein-Barr virus infected lymphoblastoid cell lines in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2009 ; 80: 498-505
70. Pender MP, Greer JM. Immunology of multiple sclerosis. Curr Allergy Asthma Rep. 2007 ; 7: 285-92 (Pubitemid 46958746)
71. Pohl D, Krone B, Rostasy K, Kahler E, Brunner E, Lehnert M. High seroprevalence of Epstein-Barr virus in children with multiple sclerosis. Neurology. 2006 ; 67: 2063-5 (Pubitemid 44967394)
72. Pudney VA, Leese AM, Rickinson AB, Hislop AD. CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells. J Exp Med. 2005 ; 201: 349-60 (Pubitemid 40229410)
73. Rand KH, Houck H, Denslow ND, Heilman KM. Epstein-Barr virus nuclear antigen-1 (EBNA-1) associated oligoclonal bands in patients with multiple sclerosis. J Neurol Sci. 2000 ; 173: 32-9 (Pubitemid 30081773)
74. Rastelli J, Hömig-Hölzel C, Seagal J, Müller W, Hermann AC, Rajewsky K. LMP1 signaling can replace CD40 signaling in B cells in vivo and has unique features of inducing class-switch recombination to IgG1. Blood. 2008 ; 111: 1448-55 (Pubitemid 351213432)
75. Reiber H, Lange P. Quantification of virus-specific antibodies in cerebrospinal fluid and serum: sensitive and specific detection of antibody synthesis in brain. Clin Chem. 1991 ; 37: 1153-60 (Pubitemid 21925939)
76. Reinherz EL, Weiner HL, Hauser SL, Cohen JA, Distaso JA, Schlossman SF. Loss of suppressor T cells in active multiple sclerosis: analysis with monoclonal antibodies. N Engl J Med. 1980 ; 303: 125-9 (Pubitemid 10076604)
77. Rickinson AB, Kieff E Fields Virology. Knipe DM Howley PM, ed. Philadelphia: Lippincott Williams & Wilkins ; 2001: 2575-627.
78. Roughan JE, Thorley-Lawson DA. The intersection of Epstein-Barr virus with the germinal center. J Virol. 2009 ; 83: 3968-76
79. Roughan JE, Torgbor C, Thorley-Lawson DA. Germinal center B cells latently infected with Epstein-Barr virus proliferate extensively but do not increase in number. J Virol. 2010 ; 84: 1158-68
80. Savoldo B, Goss JA, Hammer MM, Zhang L, Lopez T, Gee AP. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood. 2006 ; 108: 2942-9
81. Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, Cinque P. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med. 2007 ; 204: 2899-912 (Pubitemid 350179559)
82. Serafini B, Severa M, Columba-Cabezas S, Rosicarelli B, Veroni C, Chiappetta G. Epstein-Barr virus latent infection and BAFF expression in B cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B-cell activation. J Neuropathol Exp Neurol. 2010 ; 69: 677-93
83. Sibley WA, Bamford CR, Clark K. Clinical viral infections and multiple sclerosis. Lancet. 1985 ; 325: 1313-5 (Pubitemid 15059152)
84. Simon KC, Yang X, Munger KL, Ascherio A. Variation in the Epstein-Barr virus receptor, CR2, and risk of multiple sclerosis. Multiple Sclerosis. 2007 ; 13: 947-8 (Pubitemid 351540869)
85. Smets F, Latinne D, Bazin H, Reding R, Otte JB, Buts JP. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation. 2002 ; 73: 1603-10 (Pubitemid 34568673)
86. Sokal EM, Hoppenbrouwers K, Vandermeulen C, Moutschen M, Léonard P, Moreels A. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis. 2007 ; 196: 1749-53 (Pubitemid 351411934)
87. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol. 2005 ; 23: 683-747 (Pubitemid 40563183)
88. Souza TA, Stollar BD, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. Peripheral B cells latently infected with Epstein-Barr virus display molecular hallmarks of classical antigen-selected memory B cells. Proc Natl Acad Sci U S A. 2005 ; 102: 18093-8 (Pubitemid 41798507)
89. Strowig T, Gurer C, Ploss A, Liu Y, Arrey F, Sashihara J. Priming of protective T cell responses against virus-induced tumors in mice with human immune system components. J Exp Med. 2009 ; 206: 1423-34
90. Sumaya CV, Myers LW, Ellison GW. Epstein-Barr virus antibodies in multiple sclerosis. Arch Neurol. 1980 ; 37: 94-6 (Pubitemid 10174389)
91. Sumaya CV, Myers LW, Ellison GW, Ench Y. Increased prevalence and titer of Epstein-Barr virus antibodies in patients with multiple sclerosis. Ann Neurol. 1985 ; 17: 371-7 (Pubitemid 15079065)
92. Sundström P, Juto P, Wadell G, Hallmans G, Svenningsson A, Nyström L. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology. 2004 ; 62: 2277-82 (Pubitemid 38787787)
93. Tabi Z, McCombe PA, Pender MP. Apoptotic elimination of Vb8.2+ cells from the central nervous system during recovery from experimental autoimmune encephalomyelitis induced by the passive transfer of Vb8.2+ encephalitogenic T cells. Eur J Immunol. 1994 ; 24: 2609-17
94. Thacker EL, Mirzaei F, Ascherio A. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann Neurol. 2006 ; 59: 499-503 (Pubitemid 43358070)
95. Thompson AJ, Brazil J, Whelan CA, Martin EA, Hutchinson M, Feighery C. Peripheral blood T lymphocyte changes in multiple sclerosis: a marker of disease progression rather than of relapse?. J Neurol Neurosurg Psychiatry. 1986 ; 49: 905-12 (Pubitemid 16048419)
96. Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med. 2004 ; 350: 1328-37 (Pubitemid 38375368)
97. Tourtellotte WW, Potvin AR, Baumhefner RW, Potvin JH, Ma BI, Syndulko K. Multiple sclerosis de novo CNS IgG synthesis: effect of CNS irradiation. Arch Neurol. 1980 ; 37: 620-4 (Pubitemid 10018486)
98. Trotter JL, Clifford DB, McInnis JE, Griffeth RC, Bruns KA, Perlmutter MS. Correlation of immunological studies and disease progression in chronic progressive multiple sclerosis. Ann Neurol. 1989 ; 25: 172-8 (Pubitemid 19051251)
99. Tynan FE, Elhassen D, Purcell AW, Burrows JM, Borg NA, Miles JJ. The immunogenicity of a viral cytotoxic T cell epitope is controlled by its MHC-bound conformation. J Exp Med. 2005 ; 202: 1249-60 (Pubitemid 41586955)
100. Ulett G. Geographic distribution of multiple sclerosis. Dis Nerv Syst. 1948 ; 9: 342-6
101. Van Noort JM, Bajramovic JJ, Plomp AC, van Stipdonk MJB. Mistaken self, a novel model that links microbial infections with myelin-directed autoimmunity in multiple sclerosis. J Neuroimmunol. 2000 ; 105: 46-57 (Pubitemid 30125428)
102. Van Sechel AC, Bajramovic JJ, van Stipdonk MJB, Persoon-Deen C, Geutskens SB, van Noort JM. EBV-induced expression and HLA-DR-restricted presentation by human B cells of aB-crystallin, a candidate autoantigen in multiple sclerosis. J Immunol. 1999 ; 162: 129-35 (Pubitemid 29018912)
103. Veldman CM, Cantorna MT, DeLuca HF. Expression of 1,25-dihydroxyvitamin D3 receptor in the immune system. Arch Biochem Biophys. 2000 ; 374: 334-8 (Pubitemid 30120270)
104. Vetsika EK, Callan M. Infectious mononucleosis and Epstein-Barr virus. Expert Rev Mol Med. 2004 ; 6 (23). 1-16
105. Wandinger K-P, Jabs W, Siekhaus A, Bubel S, Trillenberg P, Wagner H-J. Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology. 2000 ; 55: 178-84 (Pubitemid 30604615)
106. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. Science. 2003 ; 301: 1374-77 (Pubitemid 37075812)
107. Warner HB, Carp RI. Multiple sclerosis and Epstein-Barr virus. Lancet. 1981 ; 318: 1290
108. Willis SN, Stadelmann C, Rodig SJ, Caron T, Gattenloehner S, Mallozzi SS. Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain. 2009 ; 132: 3318-28
109. Yajima M, Imadome K, Nakagawa A, Watanabe S, Terashima K, Nakamura H. A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses. J Infect Dis. 2008 ; 198: 673-82
110. Zivadinov R, Zorzon M, Weinstock-Guttman B, Serafin M, Bosco A, Bratina A. Epstein-Barr virus is associated with grey matter atrophy in multiple sclerosis. J Neurol, Neurosurg Psychiatry. 2009 ; 80: 620-5
111. ofková I, Kancheva RL. The effect of 1,25(OH)2 vitamin D3 on CD4+/CD8+ subsets of T lymphocytes in postmenopausal women. Life Sci. 1997 ; 61: 147-52 (Pubitemid 27274020)